Differences in survival and impact of adjuvant chemotherapy in patients with variant histology of tumors of the renal pelvis

[1]  P. Dasgupta,et al.  The impact of non‐urothelial variant histology on oncological outcomes following radical cystectomy , 2019, BJU international.

[2]  Myung Soo Kim,et al.  Effects of Variant Histology on the Oncologic Outcomes of Patients With Upper Urinary Tract Carcinoma After Radical Nephroureterectomy: A Propensity Score-Matched Analysis. , 2019, Clinical genitourinary cancer.

[3]  S. Lipsitz,et al.  Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle-invasive carcinoma of the bladder: Does histological subtype matter? , 2019, European Urology Supplements.

[4]  A. Kamat,et al.  Clinical and Genomic Considerations for Variant Histology in Bladder Cancer , 2019, Current Oncology Reports.

[5]  Anthony Patterson,et al.  NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[6]  D. McConkey,et al.  Molecular Subtypes of Bladder Cancer , 2018, Current Oncology Reports.

[7]  Hideaki Takahashi,et al.  Clinical outcomes of gemcitabine plus nab-paclitaxel (GnP) in initially diagnosed locally advanced pancreatic cancer. , 2018 .

[8]  J. Donovan,et al.  Results of POUT: A phase III randomised trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC). , 2018 .

[9]  M. Menon,et al.  Neoadjuvant chemotherapy prior to radical cystectomy for muscle‐invasive bladder cancer with variant histology , 2017, Cancer.

[10]  K. Hoadley,et al.  Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. , 2017, European urology.

[11]  A. Cole,et al.  Secondary data sources for health services research in urologic oncology. , 2017, Urologic oncology.

[12]  K. Moon,et al.  Variant histology as a significant predictor of survival after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma. , 2017, Urologic oncology.

[13]  M. Menon,et al.  NEOADJUVANT CHEMOTHERAPY PRIOR TO RADICAL CYSTECTOMY FOR MUSCLE‐INVASIVE BLADDER CANCER WITH VARIANT HISTOLOGY: MP34‐11 , 2017 .

[14]  E. Compérat,et al.  Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. , 2017, European urology.

[15]  S. Barni,et al.  Prognostic Factors of Overall Survival in Upper Urinary Tract Carcinoma: A Systematic Review and Meta-analysis. , 2017, Urology.

[16]  R. Fowler,et al.  Immortal time bias in observational studies of time-to-event outcomes. , 2016, Journal of critical care.

[17]  Xuesong Li,et al.  The prognostic impact of squamous and glandular differentiation for upper tract urothelial carcinoma patients after radical nephroureterectomy , 2016, World Journal of Urology.

[18]  M. Babjuk,et al.  European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. , 2015, European urology.

[19]  H. Matsuyama,et al.  Impact of variant histology on disease aggressiveness and outcome after nephroureterectomy in Japanese patients with upper tract urothelial carcinoma , 2015, International Journal of Clinical Oncology.

[20]  X. Leroy,et al.  [Pathologic analysis of upper tract urothelial carcinomas: state of the art review for the yearly scientific report of the French National Association of Urology]. , 2014, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

[21]  Steven L. Chang,et al.  A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma. , 2014, European urology.

[22]  A. Masson-Lecomte,et al.  Impact of micropapillary histological variant on survival after radical nephroureterectomy for upper tract urothelial carcinoma , 2014, World Journal of Urology.

[23]  Evan O. Paull,et al.  Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.

[24]  David A. Green,et al.  Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. , 2013, European journal of cancer.

[25]  David A. Green,et al.  Impact of histological variants on clinical outcomes of patients with upper urinary tract urothelial carcinoma. , 2012, The Journal of urology.

[26]  K. Bensalah,et al.  Subclassification of pT3 urothelial carcinoma of the renal pelvicalyceal system is associated with recurrence-free and cancer-specific survival: proposal for a revision of the current TNM classification. , 2012, European urology.

[27]  V. Margulis,et al.  Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. , 2012, European urology.

[28]  K. Bensalah,et al.  Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. , 2012, European urology.

[29]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  A. Finelli,et al.  Troubling outcomes from population-level analysis of surgery for upper tract urothelial carcinoma. , 2009, Urology.

[31]  G. Guimarães,et al.  Tissue-based molecular markers in upper tract urothelial carcinoma and their prognostic implications , 2018, International braz j urol : official journal of the Brazilian Society of Urology.

[32]  M. Zaghloul,et al.  Long-term results of primary adenocarcinoma of the urinary bladder: a report on 192 patients. , 2006, Urologic oncology.